Synthetic Biology Patents

Synthetic biology patents cover organism design and automated strain engineering innovations; synthetic DNA synthesis and gene assembly innovations; metabolic pathway engineering and biosynthesis optimization innovations; and cell-free expression and minimal genome innovations — with IP held by foundry platforms, DNA synthesis companies, fermentation specialists, and national labs: MAJOR SYNTHETIC BIOLOGY PATENT HOLDERS: GINKGO BIOWORKS: 500+; specific foundry innovations (specific specific organism design platform: specific specific automated strain engineering pipeline from specific specific high-throughput Build-Test-Learn BTL from specific specific 15,000+ strains/yr fermentation from specific specific Codebase genomic parts database from specific specific BioWorks Hub Boston foundry from specific specific Design: specific specific pathway prediction ATLAS AI from specific specific genome-scale metabolic model GSMM from specific specific Build: specific specific automated liquid handling Hamilton Tecan from specific specific OT-2 96-well 384-well from specific specific 10,000+ transformations/week from specific specific Test: specific specific LC-MS/MS metabolite quantification from specific specific HPLC 100+ product assays from specific specific Learn: specific specific Bayesian optimization GP surrogate from specific specific multi-objective Pareto strain selection); TWIST BIOSCIENCE: 300+; specific DNA synthesis innovations (specific specific silicon-based DNA synthesis: specific specific 96-well silicon chip from specific specific 200-nt oligonucleotide from specific specific error rate 1/3,000 bases vs. 1/300 column synthesis from specific specific 2 Gb/week synthesis capacity from specific specific gene assembly: specific specific Gibson assembly 1-5 kb from specific specific Golden Gate 20+ fragment from specific specific BsaI BsmBI restriction-ligation from specific specific gene synthesis 0.07$/bp vs. 0.12$/bp from specific specific variant library: specific specific 10^4-10^6 library at 200-bp from specific specific error-prone PCR MnCl₂ 1-2% diversity); AMYRIS: 500+; JBEI/DOE JOINT BIOENERGY INSTITUTE: 300+; GENENTECH/ROCHE: 3,000+; CODEX DNA / GENSCRIPT: 200+.

Metabolic pathway assembly and flux optimization innovations; directed evolution protein engineering and selection innovations; and genome-scale editing and chassis strain development innovations represent core synthetic biology patent domains: METABOLIC ENGINEERING PATENTS: AMYRIS; CODEXIS; GENOMATICA; NOVOZYMES; JBEI: specific metabolic innovations (specific specific MVA mevalonate pathway: specific specific β-farnesene: specific specific acetyl-CoA → HMGS → MVK → PMK → DXPS → IPP/DMAPP → FPP → farnesene from specific specific E. coli S. cerevisiae from specific specific rate-limiting: specific specific HMGS MK PMK IDI upregulation from specific specific downregulation ERG9 squalene from specific specific 150 g/L yeast fed-batch 200h from specific specific MEP methylerythritol phosphate pathway: specific specific E. coli isoprenoid precursor from specific specific DXS IspC IspD IspF IspH overexpression from specific specific L-tyrosine muconic acid: specific specific AroE PaAroE YdiB from specific specific catechol 1,2-dioxygenase catA from specific specific 50 g/L E. coli from specific specific 1,3-propanediol: specific specific Glycerol 3-P DhaB DhaT from specific specific DuPont Tate & Lyle 135 kg/tonne glucose from specific specific TPA terephthalic acid: specific specific Comamonas testosteroni oxygenase from specific specific isobutanol: specific specific 2-ketoisovalerate KIVD Ehrlich from specific specific Gevo 6 g/L/h from specific specific succinic acid: specific specific Basfia succiniciproducens 13 kg/L anaerobic glucose); DIRECTED EVOLUTION PATENTS: CALTECH/ARNOLD; CODEXIS; FIRMENICH; GIVAUDAN: specific directed evolution innovations (specific specific error-prone PCR: specific specific Taq MnCl₂ 0.1-0.3 mM error rate 10⁻³ per bp from specific specific StEP staggered extension from specific specific DNA shuffling family: specific specific DNase I 50-200 bp fragments from specific specific PCR reassembly from specific specific SCHEMA graph recombination from specific specific phage-assisted continuous evolution PACE: specific specific M13 phage SP DNA from specific specific lux selectable gene from specific specific 3,000 generations/week from specific specific >10¹² variants from specific specific FACS-based protein evolution: specific specific fluorescence-activated droplet from specific specific 10⁷ variants/day); GENOME EDITING PATENTS: BROAD/MIT; UC BERKELEY; CARIBOU BIOSCIENCES; INTEGRATED DNA TECHNOLOGIES: specific genome editing innovations (specific specific CRISPR-Cas9 (see separate CRISPR guide): specific specific SpCas9 NGG PAM 20-nt guide from specific specific HDR 1-10% efficiency E. coli from specific specific NHEJ mammalian dominant from specific specific Lambda Red recombineering: specific specific exo bet gam genes from specific specific 100 bp homology arm from specific specific 0.1-10% recombination E. coli from specific specific MAGE multiplex automated genome engineering: specific specific ssDNA oligo 90-mer from specific specific multiple loci simultaneously from specific specific 10⁸ variants/day from specific specific trackable barcoded library CRISPR-interference: specific specific dCas9 + sgRNA gene repression from specific specific CRISPRa activation VPR domain from specific specific 1-5 kb silent chromosome segment).

Cell-free protein synthesis CFPS extract optimization innovations; minimal genome chassis and synthetic cell innovations; and DNA data storage encoding and retrieval innovations represent additional synthetic biology patent domains: CELL-FREE PROTEIN SYNTHESIS PATENTS: SUTRO; VERDEZYNE; SYNTHERIX; NORTHWESTERN; STANFORD: specific CFPS innovations (specific specific E. coli extract CFPS: specific specific cytoplasmic S30 extract 30,000g from specific specific 3-phosphoglycerate phosphate feedstock from specific specific T7 RNA polymerase ATP 1 mM GTP from specific specific yield: specific specific 2-4 mg/mL protein 4h batch from specific specific membrane protein: specific specific liposome co-synthesis from specific specific 0.3 mg/mL GPCR vs. <10 μg cell-based from specific specific modified amino acid incorporation: specific specific amber stop UAG suppression from specific specific pyrrolysyl-tRNA PylRS from specific specific pAzF azido-phenylalanine from specific specific click chemistry bioorthogonal from specific specific virus-like particle VLP: specific specific 200-nm hollow particle from specific specific CFPS 0.5 mg/mL 60 min self-assembly from specific specific wheat germ extract WGCFPS: specific specific disulfide 3S-S eukaryotic from specific specific His-tag IMAC purification from specific specific continuous exchange CECFPS: specific specific dialysis membrane MWCO 10 kDa from specific specific 24-48h extended vs. 4h batch from specific specific 2× yield 8 mg/mL); MINIMAL GENOME PATENTS: J. CRAIG VENTER INSTITUTE JCVI; SYNTHIA; EMBL; NOVAMONT: specific minimal genome innovations (specific specific JCVI-syn3.0: specific specific 473 genes 531 kbp minimal viable genome from specific specific 149 essential unknown function from specific specific chemical synthesis 1.1 Mb from specific specific M. mycoides transplantation from specific specific synthetic cell oscillation phenotype from specific specific JCVI-syn3A: specific specific 493 genes stable division from specific specific gene cluster 19 cell division unknown from specific specific Caulobacter CB15N clean genome: specific specific 13% genome deleted from specific specific 60 non-essential gene blocks removed); DNA DATA STORAGE PATENTS: TWIST; MICROSOFT; ILLUMINA; WYSS INSTITUTE; UNIVERSITY OF WASHINGTON: specific DNA storage innovations (specific specific DNA storage density: specific specific 215 PB/gram theoretical from specific specific 100 nm 10¹⁸ molecules/gram from specific specific error-correcting code ECC: specific specific Reed-Solomon outer + inner code from specific specific HDR homologous recombination repair from specific specific LDPC from specific specific synthesis write: specific specific oligo chip 200-nt synthesis from specific specific file-to-oligo encoding from specific specific reading: specific specific NGS Illumina short-read from specific specific specific nanopore Oxford from specific specific random access: specific specific PCR amplification barcode specific specific 10^6 files addressable).

Synthetic biology startup IP strategy must navigate Genentech/Roche (3,000+) broad recombinant expression IP; understand that Ginkgo Bioworks and Amyris hold specific organism engineering and pathway IP; identify whitespace in novel pathway enzymes and regulatory elements, cell-free synthesis for complex proteins, AI-designed protein variants with improved catalytic function, and novel biosensors for high-throughput screening — while understanding that trade secret is often more protective than patents for proprietary strain libraries: SYNTHETIC BIOLOGY STARTUP IP STRATEGY: UNDERSTAND THE SYNBIO PATENT LANDSCAPE — GENENTECH AND ESTABLISHED BIOPHARMA HOLD BROAD RECOMBINANT PROTEIN EXPRESSION IP: Genentech/Roche (3,000+) holds broad CHO-based recombinant expression vector IP — this primarily affects therapeutic protein production; industrial fermentation (chemicals, flavors, materials) is less encumbered; TRADE SECRET IS OFTEN SUPERIOR TO PATENTS FOR STRAIN LIBRARIES AND METABOLIC ENGINEERING: Proprietary strain performance and process parameters are often best protected as trade secrets — a patent on a 150 g/L β-farnesene process reveals the fermentation conditions to competitors; Amyris learned this and moved toward licensing over disclosure; NOVEL ENZYME VARIANTS AND REGULATORY ELEMENTS ARE THE BEST SYNTHETIC BIOLOGY PATENT TARGETS: Novel enzymes (directed evolution products with improved kcat/KM, thermostability, pH optimum) and novel regulatory elements (promoters, RBS, terminators with measured expression levels) are the highest-value, most defensible synthetic biology IP because they can be claimed specifically and empirically measured; WHEN TO PATENT IN SYNTHETIC BIOLOGY: NOVEL ENZYME OR PATHWAY WITH MEASURED TITER/YIELD/PRODUCTIVITY IMPROVEMENT: specific novel synthetic biology invention (specific specific enzyme variant or pathway configuration + specific specific host organism + specific specific fermentation conditions) with specific measured performance (specific specific titer g/L + specific specific yield g product/g substrate + specific specific productivity g/L/h at specific specific scale L fermenter + specific specific n-fold improvement vs. wild-type enzyme or reported pathway + specific specific kcat/KM mM⁻¹s⁻¹ for enzyme variants) vs. specific specific reported literature benchmark — measured titer, yield, and productivity at scale is the single most critical synthetic biology IP metric; KEY FTO CHECKLIST: Ginkgo platform ATLAS AI GSMM BTL Hamilton Tecan OT-2 GP Bayesian; Twist silicon chip 200-nt 1/3,000 error Gibson Golden Gate BsaI 10^6 library; MVA β-farnesene HMGS IDI ERG9 150 g/L 200h yeast; MEP DXS IspC isoprenoid E. coli; L-tyrosine muconic 50 g/L; 1,3-PDO DhaB DhaT 135 kg/t; PACE M13 3,000 gen/week 10¹² variants; MAGE ssDNA 90-mer 10⁸/day; E. coli CFPS S30 2-4 mg/mL UAG pAzF; JCVI-syn3.0 473 genes 531 kbp 149 unknown; DNA storage 215 PB/g RS LDPC PCR barcode NGS nanopore.